Evidence map›Paper›PMID 29541419›Full record

ArticleOncotarget2018

The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas.

Philip Carter, Costi Alifrangis, Pramodh Chandrasinghe, Biancastella Cereser, Lisa Del Bel Belluz, Cosimo Alex Leo, Nina Moderau, Neha Tabassum, Janindra Warusavitarne, Jonathan Krell and 1 more

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Philip CarterDepartment of Surgery and Cancer, Imperial College, London, UK.
Costi AlifrangisDepartment of Medical Oncology, Imperial College, London, UK.
Pramodh ChandrasingheDepartment of Surgery and Cancer, Imperial College, London, UK.
Biancastella CereserDepartment of Surgery and Cancer, Imperial College, London, UK.
Lisa Del Bel BelluzDepartment of Surgery and Cancer, Imperial College, London, UK.
Cosimo Alex LeoDepartment of Colorectal Surgery, St Mark's Hospital, London, UK.
Nina ModerauDepartment of Surgery and Cancer, Imperial College, London, UK.
Neha TabassumDepartment of Surgery and Cancer, Imperial College, London, UK.
Janindra WarusavitarneDepartment of Colorectal Surgery, St Mark's Hospital, London, UK.
Jonathan KrellDepartment of Surgery and Cancer, Imperial College, London, UK.
Justin StebbingDepartment of Surgery and Cancer, Imperial College, London, UK.
Imperial College London · GBSt Mark's Hospital · GB

Funding

Department of Health NIHR-RP-011-053
6 · The paper itself

Abstract

We evaluated the benefit of tailoring treatments for a colorectal adenocarcinoma cancer cohort according to tumor molecular profiles, by analyzing data collected on patient responses to treatments that were guided by a tumor profiling technology from Caris Life Sciences. DNA sequencing and immunohistochemistry were the main tests that predictions were based upon, but also fragment analysis, and

Indexed as

cancer treatmentcolorectal adenocarcinomatumor profiling

Identifiers

PMID29541419
PMCPMC5834260
OpenAlexW2783880840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.